|
Concordance between blood- and tumor-based detection of RAS mutations to guide therapy in metastatic colorectal cancer. |
|
|
Travel, Accommodations, Expenses - LEO Pharma; LEO Pharma; LEO Pharma; LEO Pharma; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi |
Speakers' Bureau - Lilly; Lilly; Lilly; Lilly |
Travel, Accommodations, Expenses - Merck; Merck; Merck; Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - SERVIER; SERVIER; SERVIER; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |